Differential proteomics analysis of amniotic fluid in pregnancies of increased nuchal translucency with normal karyotype

Prenatal Diagnosis

Volumn 31, Issue 3, 2011, Pages 274-281

  Cheng, Po Jen ^a   Wang, Tzu Hao ^a   Huang, Shang Yu ^a   Kao, Chuan Chi ^a   Lu, Jen Hao ^a   Hsiao, Ching Hwa ^b   Steven Shaw, S W ^a,c  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b TAIPEI CITY HOSPITAL   (Taiwan)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Amniotic fluid; Nuchal translucency; Pregnancy; Proteomics

Indexed keywords

ALPHA 1 ANTITRYPSIN; ALPHA 1 MICROGLOBULIN; ALPHA 1B GLYCOPROTEIN PRECURSOR; ALPHA1 GLYCOPROTEIN; ALPHA2 GLYCOPROTEIN; APOLIPOPROTEIN A1; BIOLOGICAL MARKER; CERULOPLASMIN; IMMUNOGLOBULIN KAPPA CHAIN; PREALBUMIN; PROLACTIN; PROTEIN PRECURSOR; UNCLASSIFIED DRUG; ZINC ALPHA 2 GLYCOPROTEIN;

ALGORITHM; AMNION FLUID ANALYSIS; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FETUS; FUNCTIONAL PROTEOMICS; HUMAN; KARYOTYPE; MALE; MASS SPECTROMETRY; NUCHAL TRANSLUCENCY MEASUREMENT; PATHOPHYSIOLOGY; PREGNANCY; PRENATAL SCREENING; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; TWO DIMENSIONAL ELECTROPHORESIS;

ADULT; ALGORITHMS; AMNIOTIC FLUID; FEMALE; GESTATIONAL AGE; HUMANS; KARYOTYPING; MALE; NECK; NUCHAL TRANSLUCENCY MEASUREMENT; PREGNANCY; PREGNANCY PROTEINS; PREGNANCY TRIMESTER, SECOND; PROTEOMICS; ULTRASONOGRAPHY, PRENATAL; YOUNG ADULT;

EID: 79952236568     PISSN: 01973851     EISSN: 10970223     Source Type: Journal    
DOI: 10.1002/pd.2719     Document Type: Article

References (38)

1. Bole-Feysot C, Goffin V, Edery M, Binart N, Kelly PA. 1998. Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice. Endocr Rev 19: 225-268.
2. Brace RA, Moore TR. 1991. Transplacental, amniotic, urinary, and fetal fluid dynamics during very-large-volume fetal intravenous infusions. Am J Obstet Gynecol 164: 907-916.
3. Carr JM, Trygubenko SA, Wales DJ. 2005. Finding pathways between distant local minima. J Chem Phys 122: 234903.
4. Cheng PJ, Chang SD, Shaw SW, et al. 2005. Nuchal translucency thickness in fetuses with chromosomal translocation at 11-12 weeks of gestation. Obstet Gynecol 105: 1058-1062.
5. Cheng PJ, Huang SY, Shaw SW, et al. 2010a. Effect of maternal hepatitis B carrier status on first-trimester markers of Down syndrome. Reprod Sci 17: 564-567.
6. Cheng PJ, Huang SY, Shaw SW, et al. 2010b. Maternal homocysteine level and markers used in first-trimester screening for fetal Down syndrome. Reprod Sci. [Epub ahead of print]. PMID: 20876382.
7. Cheng PJ, Huang SY, Shaw SW, et al. 2010c. Evaluation of fetal spine biometry between 11 and 14 weeks of gestation. Ultrasound Med Biol 36: 1060-1065.
8. Cheng PJ, Huang SY, Shaw SW, et al. 2010d. Difference in nuchal translucency between monozygotic and dizygotic spontaneously conceived twins. Prenat Diagn 30: 247-250.
9. Cheng PJ, Liu CM, Chueh HY, et al. 2003. First-trimester nuchal translucency measurement and echocardiography at 16 to 18 weeks of gestation in prenatal detection for trisomy 18. Prenat Diagn 23: 248-251.
10. Ekins S, Bugrim A, Brovold L, et al. 2006. Algorithms for network analysis in systems-ADME/Tox using the MetaCore and MetaDrug platforms. Xenobiotica 36: 877-901.
11. Fujita J, Skold CM, Daughton DM, et al. 1999. Modulation of elastase binding to elastin by human alveolar macrophage-derived lipids. Am J Respir Crit Care Med 160: 802-807.
12. Haak MC, van Vugt JM. 2003. Pathophysiology of increased nuchal translucency: a review of the literature. Hum Reprod Update 9: 175-184.
13. Haidar B, Denis M, Marcil M, et al. 2004. Apolipoprotein A-I activates cellular cAMP signaling through the ABCA1 transporter. J Biol Chem 279: 9963-9969.
14. Handwerger S, Quarfordt S, Barrett J, et al. 1987. Apolipoproteins AI, AII, and CI stimulate placental lactogen release from human placental tissue. A novel action of high density lipoprotein apolipoproteins. J Clin Invest 79: 625-628.
15. Harris J, Stanford PM, Oakes SR, et al. 2004. Prolactin and the prolactin receptor: new targets of an old hormone. Ann Med 36: 414-425.
16. Hassan MI, Kumar V, Singh TP, et al. 2008. Proteomic analysis of human amniotic fluid from Rh(-) pregnancy. Prenatal Diagn 28: 102-108.
17. Hitti J, Lapidus JA, Lu X, et al. 2010. Noninvasive diagnosis of intraamniotic infection: proteomic biomarkers in vaginal fluid. Am J Obstet Gynecol 203: 32.e31-32.e38.
18. Hsieh S-Y, Zhuang F-H, Wu Y-T, et al. 2008. Profiling the proteome dynamics during the cell cycle of human hepatoma cells. Proteomics 8: 2872-2884.
19. Hyett J, Moscoso G, Papapanagiotou G, et al. 1996. Abnormalities of the heart and great arteries in chromosomally normal fetuses with increased nuchal translucency thickness at 11-13 weeks of gestation. Ultrasound Obstet Gynecol 7: 245-250.
20. Hyett J, Perdu M, Sharland G, et al. 1999. Using fetal nuchal translucency to screen for major congenital cardiac defects at 10-14 weeks of gestation: population based cohort study. BMJ 318: 81-85.
21. Jiao Y-L, Wu M-P. 2008. Apolipoprotein A-I diminishes acute lung injury and sepsis in mice induced by lipoteichoic acid. Cytokine 43: 83-87.
22. Kolialexi A, Anagnostopoulos AK, Mavrou A, et al. 2009. Application of proteomics for diagnosis of fetal aneuploidies and pregnancy complications. J Proteomics 72: 731-739.
23. Luo L-Y, Jiang W. 2006. Inhibition profiles of human tissue kallikreins by serine protease inhibitors. Biol Chem 387: 813-816.
24. Martinez LO, Jacquet S, Esteve J-P, et al. 2003. Ectopic beta-chain of ATP synthase is an apolipoprotein A-I receptor in hepatic HDL endocytosis. Nature 421: 75-79.
25. Mason CW, Swaan PW, Weiner CP. 2006. Identification of interactive gene networks: a novel approach in gene array profiling of myometrial events during guinea pig pregnancy. Am J Obstet Gynecol 194: 1513-1523.
26. Park SJ, Yoon WG, Song JS, et al. 2006. Proteome analysis of human amnion and amniotic fluid by two-dimensional electrophoresis and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Proteomics 6: 349-363.
27. Romero R, Espinoza J, Gotsch F, et al. 2006. The use of high-dimensional biology (genomics, transcriptomics, proteomics, and metabolomics) to understand the preterm parturition syndrome. BJOG 113(Suppl. 3): 118-135.
28. Scotet E, Martinez LO, Grant E, et al. 2005. Tumor recognition following Vgamma9Vdelta2 T cell receptor interactions with a surface F1-ATPase-related structure and apolipoprotein A-I. Immunity 22: 71-80.
29. Shaw SW, Hsieh TT, Hsu JJ, et al. 2009. Measurement of nuchal volume in the first trimester Down screening using three-dimensional ultrasound. Prenat Diagn 29: 69-73.
30. Stefansson S, Yepes M, Gorlatova N, et al. 2004. Mutants of plasminogen activator inhibitor-1 designed to inhibit neutrophil elastase and cathepsin G are more effective in vivo than their endogenous inhibitors. Journal of Biological Chemistry 279: 29981-29987.
31. Thadikkaran L, Crettaz D, Siegenthaler MA, et al. 2005. The role of proteomics in the assessment of premature rupture of fetal membranes. Clin Chim Acta 360: 27-36.
32. Wang TH, Chan YH, Chen CW, et al. 2006. Paclitaxel (Taxol) upregulates expression of functional interleukin-6 in human ovarian cancer cells through multiple signaling pathways. Oncogene 25: 4857-4866.
33. Wang TH, Chang YL, Peng HH, et al. 2005. Rapid detection of fetal aneuploidy using proteomics approaches on amniotic fluid supernatant. Prenat Diagn 25: 559-566.
34. Wang TH, Chao AS, Chen JK, et al. 2009. Network analyses of differentially expressed proteins in amniotic fluid supernatant associated with abnormal human karyotypes. Fertil Steril 92: 96-107.
35. Witters I, Fryns JR. 2007. Fetal nuchal translucency thickness. Genet Couns 18: 1-7.
36. Yamamoto M, Morita S-Y, Kumon M, et al. 2003. Effects of plasma apolipoproteins on lipoprotein lipase-mediated lipolysis of small and large lipid emulsions. Biochim Biophys Acta 1632: 31-39.
37. Yamasaki K, Schauber J, Coda A, et al. 2006. Kallikrein-mediated proteolysis regulates the antimicrobial effects of cathelicidins in skin. FASEB J 20: 2068-2080.
38. Yuhanna IS, Zhu Y, Cox BE, et al. 2001. High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase. Nat Med 7: 853-857.